Open Access Articles- Top Results for CSP-2503


Systematic (IUPAC) name
Clinical data
PubChem CID 10317515
ChemSpider 8492979 7pxY
ChEMBL CHEMBL285066 7pxY
Chemical data
Formula C22H26N4O2
378.47 g/mol
 14pxY (what is this?)  (verify)

CSP-2503 is a potent and selective 5-HT1A receptor agonist, 5-HT2A receptor antagonist, and 5-HT3 receptor antagonist of the phenylpiperazine class.[1] First synthesized in 2003, it was designed based on computational models and QSAR studies.[2][3] In rat studies, CSP-2503 has demonstrated anxiolytic effects, and thus has been suggested as a treatment for anxiety in humans with a multimodal mechanism of action.[1]

See also


  1. ^ a b Delgado M, Caicoya AG, Greciano V et al. (March 2005). "Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors". European Journal of Pharmacology 511 (1): 9–19. PMID 15777774. doi:10.1016/j.ejphar.2005.01.032. 
  2. ^ López-Rodríguez ML, Morcillo MJ, Fernández E et al. (April 2003). "Design and synthesis of S-(−)-2-[[4-(napht-1-yl)piperazin-1-yl]methyl]-1,4-dioxoperhydropyrrolo[1,2-a]pyrazine (CSP-2503) using computational simulation. A 5-HT1A receptor agonist". Bioorganic & Medicinal Chemistry Letters 13 (8): 1429–32. PMID 12668005. doi:10.1016/S0960-894X(03)00160-4. 
  3. ^ López-Rodríguez ML, Morcillo MJ, Fernández E et al. (April 2005). "Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT(1A)R agonists with selectivity over alpha1-adrenoceptors". Journal of Medicinal Chemistry 48 (7): 2548–58. PMID 15801844. doi:10.1021/jm048999e.